Dosing and sampling of the second cohort for the study concluded on Thursday, June 27, 2024, marking the completion of this phase and the end of the in-clinic portion of the study. The PK study aims to demonstrate that the Company's fingerprint sweat collection method provides results comparable to those from other specimen matrices, such as blood, saliva, and urine. INBS' first-of-its-kind fingerprint drug screening technology uses fingerprint sweat to provide a quick, hygienic, and easy-to-use method for ...